You are currently on the public version of our website. If you get any side effects from our products please talk to your doctor, pharmacist or nurse.

About us

About Us

Who We Are

A. Menarini Farmaceutica Internazionale SRL is the UK subsidiary of the Menarini Group, Italy’s largest pharmaceutical company that is headquartered in Florence. Present in 140 countries worldwide we guarantee internationally recognised quality. The family-owned group which employs around 17,000 people worldwide is one of Europe’s 20 largest producers of pharmaceutical specialities and is a successful manufacturer of pharmaceutical compounds developed in its own dedicated unit. One of the Menarini Group’s strong points is its collaboration with international partners. The Menarini Group is proud of its outstanding reputation worldwide as an efficient and reliable partner and has been committed to excellence from the very beginning.

Our UK office employs over 50 dedicated staff and is based in Buckinghamshire. The full address of our office is available below

Therapeutic and wellness areas

In the UK Menarini have established itself in the areas of cardiology, anti-infectives, and men’s health and recently launched a dermatology and aesthetic franchise RELIFE.

Our Ethics

We believe that results are achieved as a direct consequence of behaviours and actions. We strive to maintain the highest ethical standards at all times.

READ MORE

Where we are

Our UK head office houses our Pharmaceutical and Aesthetic teams and is located in High Wycombe in the South East of England.

READ MORE

MENARINI GROUP

The Menarini Group was founded in 1886 in Italy and is now present in 140 countries around the world.

Read more

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk
or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL.



Phone 0800 085 8678

Job code PP-MN-UK-0504 | Date of preparation: February 2024